Eng

Apple takes down over 30,000 games from China app store in one day

KrASIA
更新於 2020年08月03日17:29 • 發布於 2020年08月03日09:29 • Wency Chen

iPhone maker Apple has taken down more than 30,000 mobile games from its Chinese app store on August 1 according to local app data tracker Qimai, in what is the largest single removal yet of unlicensed games in a clampdown that started as early as July.

Apple removed the apps to comply with Chinese gaming regulations, which require all paid games or games with in-app purchases to be approved by the State Administration of Press, Publication, Radio, Film, and Television of China.

The company updated its rules in February this year to satisfy the regulation, which was passed in 2016, and asked developers and publishers of paid games to provide licenses by the end of June. In June, the company also informed developers in China that the removal would occur in July, KrASIA reported.

廣告(請繼續閱讀本文)

“It’s long-anticipated,” a game developer at a large Chinese internet company, who wished to remain anonymous told KrASIA. While Android app stores have long implemented the 2016 rule, Apple has kept unlicensed games online via a loophole—allowing new games to stay in the store while waiting for a license.

“[The regulation is to] maintain the user experience and environment and make sure the iOS content ecosystem is healthy,” the developer said. “If Apple didn’t comply with the regulators’ policies, the entire Chinese app store would be at risk.”

China is the biggest market for Apple. Whereas the app store ecosystem generated USD 519 billion in billings and sales worldwide in 2019, Chinese users accounted for almost half those sales, at USD 246 billion. Apple takes a 30% cut of digital transactions, the so-called “Apple Tax”.

廣告(請繼續閱讀本文)

It is unclear why Apple has waited until now to enforce the rule.

The developer told KrASIA that scrutiny from Chinese authorities probably began in 2019 when the game-license freeze ended after almost one year. The takedown proceeded slowly due to rounds of submissions and oversight as well as holidays in between.

“The removal this time hurts small and mid-sized gaming companies and indie developers most,” the developer added.

廣告(請繼續閱讀本文)

So far, 750 Chinese titles and 27 imported titles have obtained approvals this year from the regulator. Last year, 1,570 games obtained approvals.

查看原始文章

更多 Eng 相關文章

Xinhua Commentary: Chinese economy progressing well in pursuit of 2024 targets
XINHUA
LG Innotek Shines on Global Stage with Automotive Lighting Innovations
PR Newswire (美通社)
Drones relay to complete power network inspections
XINHUA
Xinhua News | Arab League condemns U.S. veto on UN resolution demanding Gaza ceasefire
XINHUA
Tourism revenue hits new high at Horgos port in Xinjiang
XINHUA
BingX Launches Spot Innovation Zone to Capture Opportunities in Bullish Markets
PR Newswire (美通社)
FedEx boosts Xiamen-U.S. cargo flight services
XINHUA
Sungrow Strengthens Australian Market Presence with 1.7GWh of C&I Energy Storage Partnerships with Raystech and Solar Juice
PR Newswire (美通社)
Proposed U.S. tariffs risk fueling inflation, slowing economic growth: economists
XINHUA
HKFDA’s Virtuose puts Hong Kong at the forefront of fashion through a stunning couture showcase
Tatler Hong Kong
CCTV+: Embarking on a Renewed Dialogue at Liangzhu Between Global Civilizations--The 'Liangzhu: A Dialogue across World Civilizations' Promotional Video and Documentary to Premier
PR Newswire (美通社)
Hanwha Power Systems signs MOU with TC Energy to accelerate commercialization of sCO2 power generation
PR Newswire (美通社)
Global Times: Neo-Chinese cuisine: How China is reimagining its food heritage
PR Newswire (美通社)
Cambodia targets 70 pct clean energy by 2030: minister
XINHUA
Turfan's Real-Time Power Response System Boosts Regional Tourism
PR Newswire (美通社)
The Global AI Defense Challenge 2024 Announces Winners Across Two Competition Tracks
PR Newswire (美通社)
Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity
PR Newswire (美通社)
Foreign guests experience vitality of urban development in China's "Spring City"
XINHUA
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
PR Newswire (美通社)
Update: China has half of top 20 science cities: Nature Index
XINHUA
APRIL Group Supports National Health Development in Riau Province, Indonesia
PR Newswire (美通社)
Deep Dive into Today's Clothing Shoppers
PR Newswire (美通社)
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
PR Newswire (美通社)
Xinjiang reaps pearl harvest through pioneering inland aquaculture
XINHUA